関連する実験動画

Updated: Apr 19, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.8K

二重特異性フォスファタゼ3の欠乏または阻害は,血小板活性化と動脈血栓形成を制限する

Lucia Musumeci1, Marijke J Kuijpers1, Karen Gilio1

  • 1From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.).

Circulation
|December 19, 2014
PubMed
まとめ

二重特異性ホスファテーゼ3 (DUSP3) は,血小板活性化と血栓形成に不可欠である. DUSP3を阻害することは,出血リスクを増加させることなく,動脈栓塞に対する新しい治療法を提供することができる.

キーワード:
アンタゴニストとインヒビータ.血小板 (血小板) とはシグナルトランスデュークション信号.トロンボシス (血栓形成) とは

さらに関連する動画

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.6K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.3K

関連する概念動画

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
11.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.2K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
7.1K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
630